Live price temporarily unavailable.
Acumen Pharmaceuticals (ABOS) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$7.91M | −$19.6M | −$45.2M | −$61.1M | −$114.0M | −$123.8M |
| Net income | −$7.33M | −$100.6M | −$42.9M | −$52.4M | −$102.3M | −$121.3M |
| EPS (diluted) | −$17.48 | −$5.02 | −$1.06 | −$1.08 | −$1.71 | −$2.00 |
| Balance sheet | ||||||
| Cash and equivalents | $43.8M | $122.2M | $130.1M | $66.9M | $35.6M | $54.0M |
| Total assets | $44.4M | $230.3M | $196.6M | $310.1M | $239.0M | $122.8M |
| Total liabilities | $6.37M | $5.15M | $7.81M | $43.2M | $57.2M | $52.4M |
| Long-term debt | — | — | $0 | $29.9M | $29.4M | $22.4M |
| Shareholders' equity | −$18.6M | $225.2M | $188.8M | $267.0M | $181.8M | $70.4M |
| Cash flow | ||||||
| Operating cash flow | −$7.45M | −$18.0M | −$35.2M | −$43.1M | −$86.2M | −$115.5M |
| Capital expenditure | — | $40.0K | $161.0K | $21.0K | $16.0K | $88.0K |
| Free cash flow | — | −$18.0M | −$35.3M | −$43.1M | −$86.2M | −$115.6M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$32.3M | −$39.6M | −$30.4M | −$41.8M | −$26.5M | −$25.2M | −$21.1M | −$32.6M |
| Net income | −$29.8M | −$37.2M | −$28.8M | −$41.0M | −$26.5M | −$25.1M | −$20.7M | −$32.7M |
| EPS (diluted) | −$0.50 | −$0.62 | −$0.48 | −$0.68 | −$0.44 | −$0.40 | −$0.33 | −$0.45 |
| Balance sheet | ||||||||
| Cash and equivalents | $33.2M | $35.6M | $30.2M | $36.8M | $46.8M | $54.0M | $51.8M | $59.4M |
| Total assets | $267.0M | $239.0M | $204.5M | $171.9M | $142.2M | $122.8M | $133.6M | $116.0M |
| Total liabilities | $49.8M | $57.2M | $49.0M | $54.8M | $49.0M | $52.4M | $46.2M | $58.7M |
| Long-term debt | $29.7M | $29.4M | $29.5M | $29.9M | $27.1M | $22.4M | $16.9M | $11.9M |
| Shareholders' equity | $217.2M | $181.8M | $155.5M | $117.1M | $93.2M | $70.4M | $87.5M | $57.3M |
| Cash flow | ||||||||
| Operating cash flow | −$24.6M | −$27.2M | −$34.1M | −$31.8M | −$30.5M | −$19.1M | −$24.1M | −$18.1M |
| Capital expenditure | $0 | $0 | $79.0K | $9.00K | $0 | $0 | $0 | $0 |
| Free cash flow | −$24.6M | −$27.2M | −$34.2M | −$31.8M | −$30.5M | −$19.1M | −$24.1M | −$18.1M |
From Acumen Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Acumen Pharmaceuticals in our feed yet.